Mylan-Biocon’s biosimilar Herceptin debuts in Australia, promising to provide patients a high quality and affordable alternative, though at least three competing trastuzumab versions including Amgen’s Kanjinti are in the wings.
First Biosimilar Trastuzumab Debuts In Australia • Source: Shutterstock
Mylan NV, which is set to combine with Pfizer Inc.’s off-patent branded and generic established medicines business, Upjohn, continues to expand its biosimilars footprint globally.
Mylan and partner Biocon Ltd. have now launched Ogivri, their biosimilar to Roche/Genentech Inc.’s Herceptin (trastuzumab) in...
